Clinical Trial Update: Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO) [Phase 2]

View source ↗

Summary

Phase 2 trial ANRS HC32 QUATTRO evaluated asunaprevir, daclatasvir, ribavirin, and pegylated interferon alfa-2a in hepatitis C genotype 4 patients who failed pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• Daclatasvir (daclatasvir)
• Pegasys (pegylated interferon alfa-2a) (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: Hepatitis C Virus Genotype 4 Infection | Phase 2 | Status: COMPLETED